Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246827 | SCV001420214 | uncertain significance | Hypertrophic cardiomyopathy 14 | 2022-07-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 971126). This variant has not been reported in the literature in individuals affected with MYH6-related conditions. This variant is present in population databases (rs535438755, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 800 of the MYH6 protein (p.Arg800His). |
Gene |
RCV002260693 | SCV002540500 | uncertain significance | not provided | 2024-05-02 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Ambry Genetics | RCV002447222 | SCV002732442 | uncertain significance | Cardiovascular phenotype | 2023-08-07 | criteria provided, single submitter | clinical testing | The p.R800H variant (also known as c.2399G>A), located in coding exon 18 of the MYH6 gene, results from a G to A substitution at nucleotide position 2399. The arginine at codon 800 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002499425 | SCV002800756 | uncertain significance | Hypertrophic cardiomyopathy 1; Dilated cardiomyopathy 1EE; Hypertrophic cardiomyopathy 14; Atrial septal defect 3; Sick sinus syndrome 3, susceptibility to | 2021-10-12 | criteria provided, single submitter | clinical testing |